HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CIR: New Research On Controversial Ingredients Should Be Considered

This article was originally published in The Rose Sheet

Executive Summary

The Cosmetic Ingredient Review Expert Panel will take a look at new research on cosmetic ingredients as needed, even if an ingredient in question is not up for review.

You may also be interested in...



CIR Adds To Hair-Care Ingredients On 2015 Priority Review List

CIR adds hair-dye ingredient 1-hydroxyethyl-4,5-diamino pyrazole sulfate and conditioning agent hydrolyzed keratin to its 2015 priority review list, which was approved during the Expert Panel’s June 9-10 meeting in Washington D.C. The panel issued final safety reports for seven ingredients and gave tentative final reports for eight substances.

CIR Gives Wheat Proteins Tentative “Safe” Review Despite Uncertainties

The CIR Expert Panel issued a tentative final safety assessment for hydrolyzed wheat protein and hydrolyzed wheat gluten at its September meeting, along with a list of stipulations in order for the ingredients to be used safely.

Preservative Methyisothiazolinone On Agenda For CIR Meeting

The American Contact Dermatitis Society names methyisothiazolinone “contact allergen of the year,” prompting the Cosmetic Ingredient Review Expert Panel to consider a possible re-review of the ingredient. The panel will discuss MIT as well as ingredients used in at-home gel manicure systems at its March 18-19 meeting in Washington, D.C.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018404

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel